# Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

Study · id `cardio:ct-nct02053909` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02053909](<https://clinicaltrials.gov/study/NCT02053909>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02053909

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.

## Technical summary

Registry record NCT02053909. Randomized; quadruple masking; primary purpose prevention. Start 2014-09 (registry gives no type); primary completion 2020-08 (actual). Results posted on 2022-09-14.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 250 participants (enrolled count; ClinicalTrials.gov record NCT02053909, source copy `cardio:ctgov-nct02053909-2022-09-14`, retrieved 2026-10-26)
- Start date: 2014-09 (registry gives no type) (ClinicalTrials.gov record NCT02053909, source copy `cardio:ctgov-nct02053909-2022-09-14`, retrieved 2026-10-26)
- Primary completion: 2020-08 (actual) (ClinicalTrials.gov record NCT02053909, source copy `cardio:ctgov-nct02053909-2022-09-14`, retrieved 2026-10-26)
- Completion: 2021-08 (actual) (ClinicalTrials.gov record NCT02053909, source copy `cardio:ctgov-nct02053909-2022-09-14`, retrieved 2026-10-26)
- Results first posted: 2022-09-14 (ClinicalTrials.gov record NCT02053909, source copy `cardio:ctgov-nct02053909-2022-09-14`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT02053909, source copy `cardio:ctgov-nct02053909-2022-09-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02053909-2022-09-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
- Acronym: TARGET
- Condition: Saphenous Vein Graft Disease
- Intervention (Drug): Aspirin
- Intervention (Drug): Ticagrelor
- Lead sponsor: Boca Raton Regional Hospital
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY
- Collaborator: Ottawa Heart Institute Research Corporation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Ottawa Heart Institute Research Corporation (`cardio:org-ottawa-heart-institute-research-corporation`)

## Provenance

Content hash: a1580ae9fade3d2ffd54959f1c810863ca505e5c663e074ad79aeb5a82af2c2f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
